Skip to main content
SLNO
NASDAQ Life Sciences

Neurocrine 收购 Soleno Therapeutics，增强罕见病产品组合

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$54
Mkt Cap
$2.039B
52W Low
$29.43
52W High
$90.32
Market data snapshot near publication time

summarizeSummary

Neurocrine Biosciences 宣布了其收购 Soleno Therapeutics 的意图，这一重大发展将整合 Soleno 的内分泌学和罕见病资产到 Neurocrine 的产品组合中。这一消息对于 Soleno Therapeutics来说具有高度的实质性意义，因为收购通常会为股东提供实质性的溢价，并从根本上改变公司的运营和战略前景。这一事件在最近的 SEC 文件或新闻中没有预示，使其成为交易者新鲜且可行的信息。投资者现在将关注交易的具体财务条款，包括每股要约价格，以及交易关闭所需的任何监管批准。

在该公告发布时，SLNO的交易价格为$54.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20.4亿。 52周交易区间为$29.43至$90.32。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed SLNO - Latest Insights

SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
HSR Waiting Period Expires for Neurocrine's Acquisition of Soleno Therapeutics
Sentiment: Positive
View Wiseek Article
SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 8:53 AM EDT
Filing Type: SC 14D9
Importance Score:
10
Soleno Board Unanimously Recommends Shareholders Accept Neurocrine's $53.00/Share All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 7:36 AM EDT
Filing Type: SC TO-T
Importance Score:
10
Neurocrine Biosciences Commences Tender Offer to Acquire Soleno Therapeutics for $53.00 Per Share in Cash
Sentiment: Positive
View Wiseek Article
SLNO
Apr 07, 2026, 1:15 PM EDT
Source: Reuters
Importance Score:
7
Soleno Withdraws EU Drug Application for Vykat XR Ahead of Neurocrine Acquisition
Sentiment: Negative
View Wiseek Article
SLNO
Apr 06, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
10
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash at $53.00 Per Share
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:39 AM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Deal
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Neurocrine to Acquire Soleno Therapeutics, Bolstering Rare Disease Portfolio
Sentiment: Positive
View Wiseek Article
SLNO
Mar 16, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
7
Soleno Therapeutics Amends Bylaws, Tightening Shareholder Proposal Rules and Adding Forum Selection
Sentiment: Neutral
View Wiseek Article